稳定期COPD接受不同疗程阿奇霉素治疗的效果分析

Stable COPD Received Different Courses of Azithromycin Treatment

目的探讨稳定期慢性阻塞性肺疾病患者接受不同疗程的阿奇霉素治疗后的肺功能改善情况。方法选取2017年2月—2018年1月我院收治的稳定期慢性阻塞性肺疾病患者108例,按照随机数字表法,分为A组、B组与C组,各36例。全部患者均接受阿奇霉素治疗,A组连续用药6个月,B组连续用药12个月,C组连续用药18个月,比较三组治疗前后肺功能、急性呼吸加重次数、6MWT与不良反应发生情况。结果 C组治疗后第1秒用力呼气容积(FEV_(1))、第1秒用力吸气容积(FVC)和FEV_(1)/FVC均高于A组与B组,B组治疗后FEV_(1)、FVC和FEV_(1)/FVC高于A组,差异有统计学意义(P <0.05);C组治疗后急性呼吸加重次数低于A组与B组,6MWT高于A组,差异有统计学意义(P <0.05);A组不良反应发生率低于B组与C组,差异有统计学意义(P <0.05);B组与C组不良反应发生率差异无统计学意义(P> 0.05)。结论稳定期慢性阻塞性肺疾病接受长期(18个月)阿奇霉素治疗后肺功能得到明显改善,且不良反应发生率低。

Objective To investigate the pulmonary function improvement of patients with stable chronic obstructive pulmonary disease after receiving different courses of azithromycin. Methods A total of 108 patients with stable chronic obstructive pulmonary disease admitted to our hospital from February 2017 to January 2018 were selected and divided into group A, Group B and group C with 36 cases each according to the random number table method. All patients were treated with azithromycin. Group A was treated with azithromycin continuously for 6 months, group B for 12 months, and group C for 18 months. Pulmonary function, number of acute respiratory exacerbations, 6 MWT and adverse reactions were compared before and after treatment in the three groups. Results Forced expiratory volume(FEV_(1)), forced inspiratory volume(FVC) and FEV_(1)/FVC in group C were all higher than those in group A and B, and FEV_(1),FVC and FEV_(1)/FVC in group B were higher than those in group A after treatment, with statistically significant differences(P < 0.05). The number of acute respiratory aggravation after treatment in group C was lower than that in group A and B, and 6 MWT was higher than that in group A, with statistically significant differences(P < 0.05). The incidence of adverse reactions in group A was lower than that in group B and C, and the difference was statistically significant(P < 0.05). There was no significant difference in the incidence of adverse reactions between group B and group C(P > 0.05).Conclusion After long-term treatment with azithromycin(18 months) for stable CHRONIC obstructive pulmonary disease, pulmonary function was significantly improved and the incidence of adverse reactions was low.